JPRN-UMIN000011805已完成3 期
A phase III study comparing interferon-alpha and zidovudine with watchful waiting for indolent adult T-cell leukemia-lymphoma (JCOG1111C, IFN/AZT vs WW for indolent ATL P-III) - IFN/AZT vs WW for indolent ATL P-III (JCOG1111C)
Japan Clinical Oncology Group (JCOG)0 个研究点目标入组 74 人开始时间: 2013年9月19日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 74
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Synchronous or metachronous malignancy 2) Active infection requiring systemic therapy 3) Body temperature >= 38 degrees Celsius 4) Pregnant or lactating women or women of childbearing potential 5) History of hypersensitivity to any of the components of the formulation in SumiferonTM 6) History of hypersensitivity to any of the components of the formulation in RetrovirTM 7) Prior allergic reactions to biological drugs including vaccines 8) Current treatment with Shosaiko-To 9) Current treatment with ibuprofen 10) Complication of autoimmune hepatitis 11) Psychiatric disease 12) Current treatment with systemic steroids 13) Poorly controlled diabetes mellitus or routine administration of insulin 14) Poorly controlled hypertension 15) Complication of unstable angina, cardiac infarction within 6 months, cardiomyopathy, cardiac failure, or arrhythmia requiring medical intervention 16) HBs-Ag positive 17) HCV-Ab positive 18) HIV-Ab positive 19) Complication of interstitial pneumonia, pulmonary fibrosis, or severe pulmonary emphysema
研究者
相似试验
终止
3 期
A Comparison of Atazanavir and Nelfinavir, Each in Combination With 2 NRTIs, in Patients Who Have Failed Treatments Without a Protease InhibitorHIV InfectionsNCT00028067Bristol-Myers Squibb500
进行中（未招募）
不适用
A 96 Week Phase IIIB Study Comparing the Antiviral Efficacy and Safety of Atazanavir/ritonavir ATV/RTV with Lopinavir/ritonavir LPV/RTV , Each in Combination with Fixed Dose Tenofovir-Emtricitabine in HIV-1 infected treatment naive subjects. - CastleHIV-1 Infected Treatment Naive subjectsMedDRA version: 6.1Level: HLTClassification code 10038997EUCTR2005-001895-11-ITBRISTOL-M.SQUIBB1,200
尚未招募
1 期
BICICL: BTK and Immune Checkpoint Inhibitor in Central Nervous System (CNS) LymphomaCentral Nervous System LymphomaCancer - Lymphoma (non Hodgkin's lymphoma) - High grade lymphomaACTRN12622000547741Monash University30
已完成
不适用
A Phase III Study Comparing the Antiviral Efficacy and Safety of BMS-232632 with Efavirenz; Each in Combination with Fixed Dose Zidovudine-Lamivudine-B22 Human immunodeficiency virus [HIV] disease resulting in other specified diseasesHuman immunodeficiency virus [HIV] disease resulting in other specified diseasesB22PER-076-00BRISTOL MYERS SQUIBB PERU S.A.,
已完成
2 期
A clinical study TO evaluate the efficacy of AYUSH drug on Covid 19 patientsCTRI/2021/08/035908Sri Sri Institute for advanced research Begaluru Karnataka50